L3VLUP
ProSign in

MTD · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MTDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MTD
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMTDVRTX
Q3 202018 holders, $3.5bn31 holders, $21.9bn
Q4 202016 holders, $3.7bn30 holders, $18.4bn
Q1 202119 holders, $3.3bn31 holders, $15.4bn
Q2 202123 holders, $3.8bn30 holders, $12.7bn
Q3 202120 holders, $3.5bn35 holders, $10.1bn
Q4 202118 holders, $4.4bn28 holders, $12.4bn
Q1 202220 holders, $3.5bn23 holders, $16.1bn
Q2 202220 holders, $2.9bn25 holders, $18.1bn
Q3 202219 holders, $2.7bn22 holders, $18.4bn
Q4 202217 holders, $3.8bn28 holders, $18.4bn
Q1 202324 holders, $4.2bn26 holders, $21.4bn
Q2 202325 holders, $3.4bn27 holders, $24.7bn
Q3 202323 holders, $1.7bn33 holders, $24.3bn
Q4 202324 holders, $2.0bn32 holders, $28.6bn
Q1 202420 holders, $2.0bn31 holders, $29.8bn
Q2 202417 holders, $2.4bn29 holders, $33.4bn
Q3 202417 holders, $2.6bn27 holders, $33.5bn
Q4 202417 holders, $1.9bn26 holders, $28.5bn
Q1 202515 holders, $2.0bn21 holders, $35.4bn
Q2 202512 holders, $2.0bn21 holders, $32.3bn
Q3 202511 holders, $2.0bn22 holders, $25.9bn
Q4 202514 holders, $2.5bn26 holders, $31.8bn
Q1 202610 holders, $2.4bn25 holders, $31.8bn
Q2 202614 holders, $3.0bn26 holders, $34.6bn
MTD

Mettler Toledo International

Holders
14
Reported value
$2.5bn
Buyers
24
Sellers
9

Breadth +15 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MTD (6)

Brevan Howard Capital Management LP, Freestone Grove Partners LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Walleye Capital LLC

Only VRTX (18)

Acadian Asset Management LLC, ARK Investment Management LLC, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →